Effects of clinical treatment decisions on long-term survival outcomes of locally advanced breast cancer with different molecular subtypes based on the SEER database

Author:

Qian Fang1,Shen Haoyuan2,Deng Chunyan3,Su Tingting4,Chen Anli1,Hu Chaohua2,Liu Chenghao2,Xu Yuanbing2,Yang Qingqing2,Hu Di4,Zhu Jiacheng4

Affiliation:

1. Postgraduate training base of the Xiaogan Central Hospital of Jinzhou Medical University, Xiaogan,432000,China

2. Department of Thyroid Gland Breast Surgery, Xiaogan Hospital Affiliated to Wuhan University of Science and Technology (Xiaogan Central Hospital), Xiaogan, 432000,China

3. Department of Pediatrics, Xiaogan Hospital Affiliated to Wuhan University of Science and Technology (Xiaogan Central Hospital), Xiaogan 432000, China

4. Xiaogan Hospital Affiliated to Wuhan University of Science and Technology, Xiaogan 432000, China

Abstract

Abstract Background: Some patients with breast cancer are diagnosed with locally advanced breast cancer (LABC). At present, there are no obvious reports on LABC radiotherapy, chemotherapy, and breast-conserving benefit population. Method: The cases of LABC confirmed by pathology from 2010 to 2015 were searched through the Surveillance Epidemiology and End Results (SEER) database. Breast cancer-specific survival (BCSS) and overall survival (OS) were estimated by plotting Kaplan-Meier curves. The log rank test (Mantel-Cox) was used to analyze the difference between the groups, and the benefit population of LABC was determined after for age, TNM stage, grade, treatment methods. Results: A total of 34474 LABC patients were included, 22477 (65.2%) were Luminal A, 1418 (4.1%) were Luminal B, 4911 (14.3%) were triple-negative breast cancer, 2461 (7.1%) were HER2-enriched, and 3207 (9.3%) were three positive breast cancer. Kaplan-Meier curves of 5-year OS and BCSS were plotted for LABC patients with different molecular types of breast conserving surgery and mastectomy. Overall the LABC with breast conserving and total mastectomy was 77.8%, 84.6% ,68.4% and 77.2%. Luminal A LABC with breast conserving and total mastectomy was 79.9%,87.5%, 72.3% and 81.5%.Luminal B LABC with breast-conserving and total mastectomy were 79.3% , 83.1%, 70.8% and 77.1%. TNBC LABC with breast-conserving and total mastectomy were 61.0% ,68.4%, 47.5% and 56.2%. HER2-enriched LABC with breast-conserving and total mastectomy were 77.7%, 80.5%, 67.2% and 75.2%. TPBC LABC with breast-conserving and total mastectomy were 84.9%, 91.8%, 75.5% and 82.1%, respectively. Except for the Luminal B LABC BCSS surgery method, there was no significant difference (P=0.058), all the others were statistically significant (P<0.05). Conclusions: This study found that in the selective population, OS and BCSS of patients with LABC undergoing breast conserving surgery were significantly better than those of mastectomy.This study also found that LABC could be considered for highly differentiated, NO stage TPBC without chemotherapy.

Publisher

Research Square Platform LLC

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3